Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures.
For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics.
Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.
-
Industry
-
Medical and Diagnostic Laboratories
-
Company size
-
2-10 employees
-
Headquarters
-
Carlsbad, California
-
Type
-
Privately Held
-
Founded
-
2004
-
Specialties
-
microbiome, colorectal cancer, molecular diagnostics, bioinformatics, inflammatory bowel disease, crohn's disease, ulcerative colitis, metagenomics, diagnostics, and computational biology
